{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T17:41:05Z","timestamp":1792172465147,"version":"4.4.0"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2024,12,9]],"date-time":"2024-12-09T00:00:00Z","timestamp":1733702400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,12,9]],"date-time":"2024-12-09T00:00:00Z","timestamp":1733702400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol Sci"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1007\/s10072-024-07920-y","type":"journal-article","created":{"date-parts":[[2024,12,9]],"date-time":"2024-12-09T01:40:24Z","timestamp":1733708424000},"page":"1833-1842","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Phenotypic patterns and response to immunotherapy in a group of Very Late Onset Myasthenia Gravis: a single center study"],"prefix":"10.1007","volume":"46","author":[{"given":"Aigli G.","family":"Vakrakou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleni","family":"Strataki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Loukas","family":"Lymperopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimitrios","family":"Panaretos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vasiliki","family":"Zouvelou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,12,9]]},"reference":[{"issue":"1","key":"7920_CR1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.25122\/jml-2020-0145","volume":"14","author":"AM Bubuioc","year":"2021","unstructured":"Bubuioc AM, Kudebayeva A, Turuspekova S, Lisnic V, Leone MA (2021) The epidemiology of myasthenia gravis. J Med Life 14(1):7\u201316","journal-title":"J Med Life"},{"issue":"5","key":"7920_CR2","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1038\/nrneurol.2016.44","volume":"12","author":"NE Gilhus","year":"2016","unstructured":"Gilhus NE, Skeie GO, Romi F, Lazaridis K, Zisimopoulou P, Tzartos S (2016) Myasthenia gravis - autoantibody characteristics and their implications for therapy. Nat Rev Neurol 12(5):259\u2013268","journal-title":"Nat Rev Neurol"},{"issue":"9","key":"7920_CR3","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1016\/j.autrev.2013.03.001","volume":"12","author":"JJ Verschuuren","year":"2013","unstructured":"Verschuuren JJ, Huijbers MG, Plomp JJ, Niks EH, Molenaar PC, Martinez-Martinez P et al (2013) Pathophysiology of myasthenia gravis with antibodies to the acetylcholine receptor, muscle-specific kinase and low-density lipoprotein receptor-related protein 4. Autoimmun Rev 12(9):918\u2013923","journal-title":"Autoimmun Rev"},{"issue":"10","key":"7920_CR4","doi-asserted-by":"publisher","first-page":"1888","DOI":"10.1212\/WNL.42.10.1888","volume":"42","author":"LH Phillips 2nd","year":"1992","unstructured":"Phillips LH 2nd, Torner JC, Anderson MS, Cox GM (1992) The epidemiology of myasthenia gravis in central and western Virginia. Neurology 42(10):1888\u20131893","journal-title":"Neurology"},{"issue":"6","key":"7920_CR5","doi-asserted-by":"publisher","first-page":"1024","DOI":"10.1212\/01.WNL.0000050461.05432.C5","volume":"60","author":"JM Aragon\u00e8s","year":"2003","unstructured":"Aragon\u00e8s JM, Bol\u00edbar I, Bonfill X, Bufill E, Mummany A, Alonso F et al (2003) Myasthenia gravis: a higher than expected incidence in the elderly. Neurology 60(6):1024\u20131026","journal-title":"Neurology"},{"issue":"1","key":"7920_CR6","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1001\/archneur.56.1.25","volume":"56","author":"JA Aarli","year":"1999","unstructured":"Aarli JA (1999) Late-onset myasthenia gravis: a changing scene. Arch Neurol 56(1):25\u201327","journal-title":"Arch Neurol"},{"key":"7920_CR7","doi-asserted-by":"crossref","unstructured":"Somnier FE, Keiding N, Paulson OB (1991) Epidemiology of myasthenia gravis in Denmark. A longitudinal and comprehensive population survey. Arch Neurol 48(7):733\u20139","DOI":"10.1001\/archneur.1991.00530190081019"},{"issue":"5","key":"7920_CR8","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1002\/mus.23964","volume":"48","author":"NM Alkhawajah","year":"2013","unstructured":"Alkhawajah NM, Oger J (2013) Late-onset myasthenia gravis: a review when incidence in older adults keeps increasing. Muscle Nerve 48(5):705\u2013710","journal-title":"Muscle Nerve"},{"issue":"8","key":"7920_CR9","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1136\/jnnp.74.8.1105","volume":"74","author":"A Vincent","year":"2003","unstructured":"Vincent A, Clover L, Buckley C, Grimley Evans J, Rothwell PM (2003) Evidence of underdiagnosis of myasthenia gravis in older people. J Neurol Neurosurg Psychiatry 74(8):1105\u20131108","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"11","key":"7920_CR10","doi-asserted-by":"publisher","first-page":"e1171","DOI":"10.1212\/WNL.0000000000008903","volume":"94","author":"E Cort\u00e9s-Vicente","year":"2020","unstructured":"Cort\u00e9s-Vicente E, \u00c1lvarez-Velasco R, Segovia S, Paradas C, Casasnovas C, Guerrero-Sola A et al (2020) Clinical and therapeutic features of myasthenia gravis in adults based on age at onset. Neurology 94(11):e1171\u2013e1180","journal-title":"Neurology"},{"issue":"4","key":"7920_CR11","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1002\/mus.27369","volume":"64","author":"J Vijayan","year":"2021","unstructured":"Vijayan J, Menon D, Barnett C, Katzberg H, Lovblom LE, Bril V (2021) Clinical profile and impact of comorbidities in patients with very-late-onset myasthenia gravis. Muscle Nerve 64(4):462\u2013466","journal-title":"Muscle Nerve"},{"key":"7920_CR12","doi-asserted-by":"crossref","unstructured":"Jaretzki A, 3rd, Barohn RJ, Ernstoff RM, Kaminski HJ, Keesey JC, Penn AS et al (2000) Myasthenia gravis: recommendations for clinical research standards. Task Force of the Medical Scientific Advisory Board of the Myasthenia Gravis Foundation of America. Neurology 55(1):16\u201323","DOI":"10.1212\/WNL.55.1.16"},{"issue":"1","key":"7920_CR13","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.nmd.2015.10.009","volume":"26","author":"A Breiner","year":"2016","unstructured":"Breiner A, Widdifield J, Katzberg HD, Barnett C, Bril V, Tu K (2016) Epidemiology of myasthenia gravis in Ontario, Canada. Neuromuscul Disord NMD 26(1):41\u201346","journal-title":"Neuromuscul Disord NMD"},{"key":"7920_CR14","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2022.857402","volume":"13","author":"S Zhao","year":"2022","unstructured":"Zhao S, Yan X, Ding J, Ren K, Sun S, Lu J et al (2022) Lack of immunotherapy as the only predictor of secondary generalization in very-late-onset myasthenia gravis with pure ocular onset. Front Neurol 13:857402","journal-title":"Front Neurol"},{"key":"7920_CR15","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1186\/s42466-020-00091-z","volume":"2","author":"F Pasqualin","year":"2020","unstructured":"Pasqualin F, Guidoni SV, Ermani M, Pegoraro E, Bonifati DM (2020) Outcome measures and treatment effectiveness in late onset myasthenia gravis. Neurol Res Pract 2:45","journal-title":"Neurol Res Pract"},{"issue":"8","key":"7920_CR16","doi-asserted-by":"publisher","first-page":"1314","DOI":"10.1007\/s00415-009-5120-8","volume":"256","author":"MJ Kupersmith","year":"2009","unstructured":"Kupersmith MJ (2009) Ocular myasthenia gravis: treatment successes and failures in patients with long-term follow-up. J Neurol 256(8):1314\u20131320","journal-title":"J Neurol"},{"issue":"3","key":"7920_CR17","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1136\/practneurol-2015-001126","volume":"15","author":"J Sussman","year":"2015","unstructured":"Sussman J, Farrugia ME, Maddison P, Hill M, Leite MI, Hilton-Jones D (2015) Myasthenia gravis: association of British Neurologists\u2019 management guidelines. Pract Neurol 15(3):199\u2013206","journal-title":"Pract Neurol"},{"issue":"1","key":"7920_CR18","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1007\/s00415-023-11970-1","volume":"271","author":"V Di Stefano","year":"2024","unstructured":"Di Stefano V, Alonge P, Rini N, Militello M, Lupica A, Torrente A et al (2024) Efgartigimod beyond myasthenia gravis: the role of FcRn-targeting therapies in stiff-person syndrome. J Neurol 271(1):254\u2013262","journal-title":"J Neurol"},{"issue":"11","key":"7920_CR19","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1001\/jamaneurol.2022.2887","volume":"79","author":"F Piehl","year":"2022","unstructured":"Piehl F, Eriksson-Dufva A, Budzianowska A, Feresiadou A, Hansson W, Hietala MA et al (2022) Efficacy and safety of Rituximab for new-onset generalized myasthenia gravis: the RINOMAX randomized clinical trial. JAMA Neurol 79(11):1105\u20131112","journal-title":"JAMA Neurol"},{"issue":"6","key":"7920_CR20","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1002\/mus.27393","volume":"64","author":"CT Doughty","year":"2021","unstructured":"Doughty CT, Suh J, David WS, Amato AA, Guidon AC (2021) Retrospective analysis of safety and outcomes of rituximab for myasthenia gravis in patients \u226565 years old. Muscle Nerve 64(6):651\u2013656","journal-title":"Muscle Nerve"},{"key":"7920_CR21","doi-asserted-by":"crossref","unstructured":"Nishikawa N, Nagai M, Tsujii T, Kyaw WT, Tanabe N, Iwaki H et al (2015) Treatment of myasthenia gravis in patients with elderly onset at advanced age. Japanese Clin Med 6:9\u201313","DOI":"10.4137\/JCM.S29601"},{"issue":"12","key":"7920_CR22","doi-asserted-by":"publisher","first-page":"416","DOI":"10.33588\/rn.7312.2021166","volume":"73","author":"E Mart\u00ednez-Monte","year":"2021","unstructured":"Mart\u00ednez-Monte E, Gasc\u00f3n-Gim\u00e9nez F, Dom\u00ednguez-Mor\u00e1n JA, L\u00e1inez-Andres JM (2021) Rituximab for the treatment of generalised myasthenia gravis: experience in clinical practice. Rev Neurol 73(12):416\u2013420","journal-title":"Rev Neurol"},{"issue":"3","key":"7920_CR23","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1002\/mus.26876","volume":"62","author":"SK Sahai","year":"2020","unstructured":"Sahai SK, Maghzi AH, Lewis RA (2020) Rituximab in late-onset myasthenia gravis is safe and effective. Muscle Nerve 62(3):377\u2013380","journal-title":"Muscle Nerve"},{"issue":"10","key":"7920_CR24","doi-asserted-by":"publisher","first-page":"2167","DOI":"10.1007\/s00415-012-6478-6","volume":"259","author":"SA Zivkovi\u0107","year":"2012","unstructured":"Zivkovi\u0107 SA, Clemens PR, Lacomis D (2012) Characteristics of late-onset myasthenia gravis. J Neurol 259(10):2167\u20132171","journal-title":"J Neurol"},{"issue":"5","key":"7920_CR25","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1212\/WNL.40.5.786","volume":"40","author":"DH Donaldson","year":"1990","unstructured":"Donaldson DH, Ansher M, Horan S, Rutherford RB, Ringel SP (1990) The relationship of age to outcome in myasthenia gravis. Neurology 40(5):786\u2013790","journal-title":"Neurology"},{"key":"7920_CR26","volume":"2011","author":"F Romi","year":"2011","unstructured":"Romi F (2011) Thymoma in myasthenia gravis: from diagnosis to treatment. Autoimmune Dis 2011:474512","journal-title":"Autoimmune Dis"},{"issue":"7","key":"7920_CR27","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1080\/1744666X.2021.1936500","volume":"17","author":"A Evoli","year":"2021","unstructured":"Evoli A, Spagni G, Monte G, Damato V (2021) Heterogeneity in myasthenia gravis: considerations for disease management. Expert Rev Clin Immunol 17(7):761\u2013771","journal-title":"Expert Rev Clin Immunol"},{"issue":"4","key":"7920_CR28","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1097\/CND.0b013e31828a0090","volume":"14","author":"GZ Huang","year":"2013","unstructured":"Huang GZ, Lo YL (2013) Correlation between acetylcholine receptor antibody levels and thymic pathology in myasthenia gravis: a review. J Clin Neuromuscul Dis 14(4):209\u2013217","journal-title":"J Clin Neuromuscul Dis"},{"issue":"9","key":"7920_CR29","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1016\/j.autrev.2013.03.007","volume":"12","author":"A Marx","year":"2013","unstructured":"Marx A, Pfister F, Schalke B, Saruhan-Direskeneli G, Melms A, Str\u00f6bel P (2013) The different roles of the thymus in the pathogenesis of the various myasthenia gravis subtypes. Autoimmun Rev 12(9):875\u2013884","journal-title":"Autoimmun Rev"},{"key":"7920_CR30","doi-asserted-by":"crossref","unstructured":"Sakai W, Matsui N, Ishida M, Furukawa T, Miyazaki Y, Fujita K et al (2016) Late-onset myasthenia gravis is predisposed to become generalized in the elderly. eNeurologicalSci 2:17\u201320","DOI":"10.1016\/j.ensci.2016.02.004"},{"issue":"1\u20132","key":"7920_CR31","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jns.2012.10.028","volume":"325","author":"MA Hellmann","year":"2013","unstructured":"Hellmann MA, Mosberg-Galili R, Steiner I (2013) Myasthenia gravis in the elderly. J Neurol Sci 325(1\u20132):1\u20135","journal-title":"J Neurol Sci"}],"container-title":["Neurological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10072-024-07920-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10072-024-07920-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10072-024-07920-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,18]],"date-time":"2025-03-18T17:59:44Z","timestamp":1742320784000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10072-024-07920-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,9]]},"references-count":31,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["7920"],"URL":"https:\/\/doi.org\/10.1007\/s10072-024-07920-y","relation":{},"ISSN":["1590-1874","1590-3478"],"issn-type":[{"value":"1590-1874","type":"print"},{"value":"1590-3478","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,9]]},"assertion":[{"value":"30 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 November 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 December 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"None of the authors has any conflict of interest to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The studies involving human participants were reviewed and approved by Ethics Committees of the Aeginition Hospital (612\/28.03.2024). The study was performed in accordance with the ethical standards as laid down in the 1964 Declaration of Helsinki. Written informed consent for participation was obtained by all patients in accordance with the national legislation and the institutional requirements.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and Informed consent"}},{"value":"We confirm that we have read the Journal\u2019s position on issues involved in ethical publication and affirm that this report is consistent with those guidelines.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical publication statement"}}]}}